Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Dr Véronique Walsh, VP and GM at Gilead Sciences UK & Ireland, commented: “This news comes at a time when new hospitals are preparing to deliver CAR-T cell therapies and will mean that ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...